论文部分内容阅读
目的观察多西他赛联合放疗治疗Ⅲ期非小细胞肺癌患者的临床效果。方法选取医院收治的Ⅲ期非小细胞肺癌患者98例为研究对象,随机分为观察组和对照组,每组49例。对照组采用放射治疗,观察组采用多西他赛联合放疗治疗,观察2组患者治疗效果、不良反应发生率及生存时间。结果观察组总有效率为93.88%,高于对照组的71.43%(P<0.01);观察组不良反应发生率为28.57%,低于对照组的67.35%(P<0.01);观察组生存时间为(25.47±0.24)个月,长于对照组的(10.21±0.64)个月(P<0.01)。结论多西他赛联合放疗治疗Ⅲ期非小细胞肺癌患者的临床效果较显著,可有效延长患者的生存时间,不良反应发生率较低,值得临床推广应用。
Objective To observe the clinical effect of docetaxel combined with radiotherapy in the treatment of stage Ⅲ non-small cell lung cancer. Methods A total of 98 patients with stage Ⅲ non-small cell lung cancer admitted to the hospital were selected as study subjects and randomly divided into observation group and control group, 49 cases in each group. The control group was treated with radiotherapy. The observation group was treated with docetaxel combined with radiotherapy. The therapeutic effect, incidence of adverse reactions and survival time were observed in the two groups. Results The total effective rate in the observation group was 93.88%, which was higher than 71.43% in the control group (P <0.01). The adverse reaction rate in the observation group was 28.57%, which was lower than 67.35% in the control group (P <0.01) (25.47 ± 0.24) months, longer than the control group (10.21 ± 0.64) months (P <0.01). Conclusion Docetaxel combined with radiotherapy for the treatment of stage Ⅲ non-small cell lung cancer patients with more significant clinical effect, which can effectively prolong the survival time of patients, the incidence of adverse reactions is low, worthy of clinical application.